Patient Perspectives and Clinical Insights Into the Diagnostic Journey From Connective Tissue Disease to Pulmonary Arterial Hypertension.

IF 3.4 2区 医学 Q2 RHEUMATOLOGY Journal of Rheumatology Pub Date : 2025-05-01 DOI:10.3899/jrheum.2024-0613
Kristin B Highland, Rumon Chakravarty, Sylvia Georgi, Michelle Han
{"title":"Patient Perspectives and Clinical Insights Into the Diagnostic Journey From Connective Tissue Disease to Pulmonary Arterial Hypertension.","authors":"Kristin B Highland, Rumon Chakravarty, Sylvia Georgi, Michelle Han","doi":"10.3899/jrheum.2024-0613","DOIUrl":null,"url":null,"abstract":"<p><p>Plain Language SummaryPeople with connective tissue disorders (CTDs), like systemic lupus erythematosus (SLE), mixed CTD, and systemic sclerosis (SSc), are at risk for a lung condition called pulmonary arterial hypertension (PAH). Since PAH gets worse over time if it is not treated, it is important for anyone with PAH to be diagnosed and treated with medication as early as possible. This article describes the experiences of 4 adults who have CTD and PAH, including their journey of being diagnosed with CTD and then PAH, which healthcare providers they saw, and the types of information they were given to learn about their conditions. All 4 people described having a rash as their first symptom of CTD, and said their symptoms got worse over time, which made them see their primary care provider. Two people felt their doctor dismissed their symptoms. Everyone was eventually referred to a rheumatologist or dermatologist and diagnosed with a type of CTD: 1 had SLE, 2 had mixed CTD, and 1 had SSc. Only 1 person was told that having a CTD meant they had a higher risk of getting PAH. It took between 2 and 11 years after their CTD diagnosis to be diagnosed with PAH, all while they were at risk for more intense PAH symptoms. The group recommended better education for doctors and support staff about CTD, so that they are able to screen their patients for PAH, recognize the disease, and quickly refer patients to PAH specialists at accredited pulmonary hypertension centers for further testing.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"515-519"},"PeriodicalIF":3.4000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3899/jrheum.2024-0613","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Plain Language SummaryPeople with connective tissue disorders (CTDs), like systemic lupus erythematosus (SLE), mixed CTD, and systemic sclerosis (SSc), are at risk for a lung condition called pulmonary arterial hypertension (PAH). Since PAH gets worse over time if it is not treated, it is important for anyone with PAH to be diagnosed and treated with medication as early as possible. This article describes the experiences of 4 adults who have CTD and PAH, including their journey of being diagnosed with CTD and then PAH, which healthcare providers they saw, and the types of information they were given to learn about their conditions. All 4 people described having a rash as their first symptom of CTD, and said their symptoms got worse over time, which made them see their primary care provider. Two people felt their doctor dismissed their symptoms. Everyone was eventually referred to a rheumatologist or dermatologist and diagnosed with a type of CTD: 1 had SLE, 2 had mixed CTD, and 1 had SSc. Only 1 person was told that having a CTD meant they had a higher risk of getting PAH. It took between 2 and 11 years after their CTD diagnosis to be diagnosed with PAH, all while they were at risk for more intense PAH symptoms. The group recommended better education for doctors and support staff about CTD, so that they are able to screen their patients for PAH, recognize the disease, and quickly refer patients to PAH specialists at accredited pulmonary hypertension centers for further testing.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
从结缔组织疾病到肺动脉高压的诊断过程中的患者观点和临床见解。
结缔组织疾病(CTDs)患者,如系统性红斑狼疮(SLE)、混合性CTD和系统性硬化症(SSc),都有患肺动脉高压(PAH)的风险。由于如果不治疗,多环芳烃会随着时间的推移而恶化,因此对任何患有多环芳烃的人来说,尽早诊断并接受药物治疗是很重要的。本文描述了4名患有CTD和PAH的成年人的经历,包括他们被诊断为CTD和PAH的过程,他们看了哪些医疗保健提供者,以及他们被告知了解自己病情的信息类型。所有4人都将皮疹描述为CTD的第一个症状,并表示他们的症状随着时间的推移而恶化,这让他们去看了他们的初级保健提供者。两个人觉得他们的医生忽视了他们的症状。每个人最终都被转诊到风湿病学家或皮肤科医生那里,并被诊断出患有某种类型的CTD: 1人患有SLE, 2人患有混合性CTD, 1人患有SSc。只有1人被告知有CTD意味着他们患多环芳烃的风险更高。在他们被诊断为CTD后的2到11年之间,他们被诊断为多环芳烃,而这期间他们有更严重的多环芳烃症状的风险。该小组建议对医生和辅助人员进行更好的CTD教育,以便他们能够筛查患者的PAH,识别疾病,并迅速将患者转介给经认可的肺动脉高压中心的PAH专家进行进一步检查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Rheumatology
Journal of Rheumatology 医学-风湿病学
CiteScore
6.50
自引率
5.10%
发文量
285
审稿时长
1 months
期刊介绍: The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman. The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 41 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.
期刊最新文献
Comparing Novel and Legacy Health Assessment Questionnaire Scoring Methods: A Scleroderma Patient-centered Intervention Network Cohort Study. Risk of Spondyloarthritis in Patients With Inflammatory Bowel Disease Receiving Treatment With Biologics or Janus Kinase Inhibitors. The Use of Real-World Data for Studies of Dynamic Disease Processes. Individual and Socioecological Resilience in Childhood-Onset Systemic Lupus Erythematosus: Associations With Patient Characteristics and Psychosocial Patient-Reported Outcomes. Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis and Its Association With Risk of Major Adverse Cardiac Events.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1